Evidence map›Paper›PMID 21686123›Full record

ArticleFrontiers in microbiology2011

Francisella Subverts Innate Immune Signaling: Focus On PI3K/Akt.

Thomas John Cremer, Jonathan P Butchar, Susheela Tridandapani

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. The immune response toFrontiers in microbiology · 2025
    Review
  2. Transcriptional Studies onFrontiers in cellular and infection microbiology · 2021
    Review
  3. Article
  4. Review
  5. The Early Dendritic Cell Signaling Induced by VirulentMolecular & cellular proteomics : MCP · 2018
    Article
  6. Article
  7. The Effect of MicroRNA-375 Overexpression, an Inhibitor ofJundishapur journal of microbiology · 2016
    Article
  8. Article
  9. Article
  10. Tularaemia: a challenging zoonosis.Comparative immunology, microbiology and infectious diseases · 2014
    Review
  11. Article
  12. Review
  13. Comparative review of Francisella tularensis and Francisella novicida.Frontiers in cellular and infection microbiology · 2014
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Thomas John CremerDepartment of Internal Medicine, The Ohio State University Medical Center Columbus, OH, USA.
Jonathan P Butchar
Susheela Tridandapani

Funding

Vaccines and Therapies Against BotulismU54AI057153 · NIAID · UNIVERSITY OF CHICAGO · PI SCHLESINGER, LARRY S. · 2003 to 2013
$87.6M
Interdisciplinary Study of the Microbe-Host InterfaceT32AI065411 · NIAID · OHIO STATE UNIVERSITY · PI SCHLESINGER, LARRY S. · 2007 to 2011
$592k
NIAID NIH HHS T32 AI065411NIAID NIH HHS U54 AI057153
6 · The paper itself

Abstract

Intracellular bacterial pathogens exploit host cells as a part of their lifecycle, and they do so by manipulating host cell signaling events. Many such bacteria are known to produce effector proteins that promote cell invasion, alter membrane trafficking, and disrupt signaling cascades. This review highlights recent advances in our understanding of signaling pathways involved in host cell responses to Francisella tularensis, a facultative Gram-negative intracellular pathogen that causes tularemia. We highlight several key pathways that are targeted by Francisella, with a focus on the phosphatidylinositol 3-kinase/Akt pathway. Lastly, we discuss the emerging role of microRNAs (miRs), specifically miR-155, as a key regulator of host signaling and defense.

Indexed as

AktFrancisellahost responsemiR-155PI3KSHIP

Identifiers

PMID21686123
PMCPMC3109490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.